|Other Names||Glycylpeptide N-tetradecanoyltransferase 2, Myristoyl-CoA:protein N-myristoyltransferase 2, NMT 2, Peptide N-myristoyltransferase 2, Type II N-myristoyltransferase, NMT2|
|Target/Specificity||The synthetic peptide sequence is selected from aa 31~46 of human NMT2.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Adds a myristoyl group to the N-terminal glycine residue of certain cellular and viral proteins.|
|Cellular Location||Cytoplasm. Membrane; Peripheral membrane protein|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
N-myristoyltransferase (NMT) catalyzes the reaction of N-terminal myristoylation of many signaling proteins. It transfers myristic acid from myristoyl coenzyme A to the amino group of a protein's N-terminal glycine residue. Biochemical evidence indicates the presence of several distinct NMTs, varying in apparent molecular weight and /or subcellular distribution. The predicted 498-amino acid of human NMT2 protein shares 77% and 96% sequence identity with human NMT1 and mouse Nmt2 comprise two distinct families of N-myristoyltransferases.
Lindwasser, O.W., et al., Proc. Natl. Acad. Sci. U.S.A. 99(20):13037-13042 (2002).Kolluri, S.K., et al., Cancer Res. 61(23):8534-8539 (2001).Shiraishi, T., et al., Biochem. Biophys. Res. Commun. 282(5):1201-1205 (2001).Ono, A., et al., J. Virol. 73(5):4136-4144 (1999).Paillart, J.C., et al., J. Virol. 73(4):2604-2612 (1999).
If you have any additional inquiries please email technical services at email@example.com.